9N0Y image
Deposition Date 2025-01-24
Release Date 2025-06-18
Last Version Date 2025-07-09
Entry Detail
PDB ID:
9N0Y
Keywords:
Title:
PP2A-B55 Holoenzyme with Eya3
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.71 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform
Gene (Uniprot):PPP2R1A
Chain IDs:A
Chain Length:584
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform
Gene (Uniprot):PPP2R2A
Chain IDs:B
Chain Length:451
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform
Gene (Uniprot):PPP2CA
Chain IDs:C
Chain Length:309
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Protein phosphatase EYA3
Gene (Uniprot):EYA3
Chain IDs:D
Chain Length:573
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Cryo-EM structures reveal the PP2A-B55 alpha and Eya3 interaction that can be disrupted by a peptide inhibitor.
J.Biol.Chem. 301 110287 110287 (2025)
PMID: 40414499 DOI: 10.1016/j.jbc.2025.110287

Abstact

We have previously shown that Eya3 recruits PP2A-B55α to dephosphorylate pT58 on Myc, increasing Myc stability and enhancing primary tumor growth of triple-negative breast cancer (TNBC). However, the molecular details of how Eya3 recruits PP2A-B55α remain unclear. Here we determined the cryo-EM structures of PP2A-B55α bound with Eya3, with an inhibitory peptide B55i, and in its unbound state. These studies demonstrate that Eya3 binds B55α through an extended peptide in the NTD of Eya3. The Eya3 peptide, PP2A-B55α substrates, and protein/peptide inhibitors including B55i bind to a similar area on the B55α surface but the molecular details of the binding differ. We further demonstrated that the B55i peptide inhibits the B55α and Eya3 interaction in vitro. The B55i peptide expressed on a plasmid increases Myc pT58 and decreases Myc protein levels in TNBC cells, suggesting the potential of B55i or similar peptides as therapies for TNBC.

Legend

Protein

Chemical

Disease

Primary Citation of related structures